New AMP testing recommendations for alleles in CYP3A4 and CYP3A5

The Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase have jointly published recommendations on what constitutes the minimum panel of variant alleles (tier 1) and an extended panel of variant alleles (tier 2) for CYP3A4 and CYP3A5 [PMID:337419245].

Tier 1 CYP3A4*22, CYP3A5*3, CYP3A5*6, CYP3A5*7Tier 2 CYP3A4*20

PharmGKB maintains the lists for these alleles and the tier 1 and tier 2 alleles previously published for CYP2C19, CYP2C9, VKORC1, TPMT. NUDT15 at https://www.pharmgkb.org/ampAllelesToTestWhen on an allele page there is a tag to show if this allele is part of the recommended test set:

When on a gene page there is a tag to show the gene has an AMP set of test alleles plus there is a link to the AMP page from the VIP summary.